Janus Henderson Group
JANX icon

Janus Henderson Group’s Janux Therapeutics JANX Stock Holding History

Janus Henderson Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.3M Sell
4,196,409
-1,154,044
-22% -$15.8M 0.03% 380
2025
Q4 		$73.9M Buy
5,350,453
+649,341
+14% +$15.3M 0.03% 344
2025
Q3 		$115M Buy
4,701,112
+240,780
+5% +$5.86M 0.05% 257
2025
Q2 		$103M Sell
4,460,332
-137,760
-3% -$3.63M 0.05% 257
2025
Q1 		$134M Buy
4,598,092
+1,035,690
+29% +$39M 0.07% 227
2024
Q4 		$191M Buy
3,562,402
+1,038,996
+41% +$55M 0.1% 198
2024
Q3 		$115M Buy
2,523,406
+721,563
+40% +$31.4M 0.06% 257
2024
Q2 		$75.4M Sell
1,801,843
-163,703
-8% -$7.69M 0.04% 302
2024
Q1 		$74M Buy
1,965,546
+34,069
+2% +$742K 0.04% 314
2023
Q4 		$20.7M Sell
1,931,477
-135,991
-7% -$1.18M 0.01% 541
2023
Q3 		$20.8M Sell
2,067,468
-41,870
-2% -$483K 0.01% 521
2023
Q2 		$25M Buy
2,109,338
+240,262
+13% +$3.21M 0.02% 519
2023
Q1 		$22.6M Buy
1,869,076
+31,285
+2% +$521K 0.01% 550
2022
Q4 		$24.2M Sell
1,837,791
-122,253
-6% -$1.79M 0.02% 525
2022
Q3 		$26.5M Sell
1,960,044
-167,753
-8% -$2.24M 0.02% 503
2022
Q2 		$26M Sell
2,127,797
-211,349
-9% -$2.5M 0.02% 516
2022
Q1 		$33.5M Sell
2,339,146
-61,747
-3% -$1.01M 0.02% 619
2021
Q4 		$46.6M Sell
2,400,893
-15,511
-0.6% -$325K 0.02% 566
2021
Q3 		$51.4M Sell
2,416,404
-251,803
-9% -$7.24M 0.02% 546
2021
Q2 		$64.5M Buy
+2,668,207
New +$59.4M 0.03% 502

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Janus Henderson Group's JANX Position: Q1 2026 in Review

Janus Henderson Group reduced its Janux Therapeutics (JANX) stake by 22% in Q1 2026, selling an estimated $15.8M and leaving 4,196,409 shares worth $58.3M. The position accounts for 0.03% of the portfolio, ranked #380.

Janus Henderson Group first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $191M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Janus Henderson Group held 4,196,409 shares of Janux Therapeutics worth $58.3M as of Q1 2026.
  • Janus Henderson Group sold 1,154,044 Janux Therapeutics shares in Q1 2026, an estimated $15.8M.
  • Janux Therapeutics made up 0.03% of Janus Henderson Group's portfolio in Q1 2026, its #380 holding.
  • Janus Henderson Group first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Janus Henderson Group's Janux Therapeutics position peaked at $191M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.